Jazz Pharmaceuticals JAZZ Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's investing cash flow?
- Jazz Pharmaceuticals (JAZZ) reported investing cash flow of $123.1M in Q1 2026.
- How has Jazz Pharmaceuticals's investing cash flow changed year-over-year?
- Jazz Pharmaceuticals's investing cash flow increased by 172.8% year-over-year, from -$169M to $123.1M.
- What is the long-term trend for Jazz Pharmaceuticals's investing cash flow?
- Over 2 years (2021 to 2025), Jazz Pharmaceuticals's investing cash flow has grown at a -46.2% compound annual growth rate (CAGR), from -$5.21B to -$1.51B.
- What does investing cash flow mean?
- The net cash balance from all investing activities.
- How do you interpret investing cash flow?
- Negative values typically indicate capital deployment for growth, while positive values may indicate asset liquidation or divestment.
- How does investing cash flow compare across companies?
- Highly variable based on the company's growth stage and M&A activity.